file_download Download slide in HQ

Index for
slide deck

Title

Shorter Duration of Psychosis Led to Improved Outcomes in Patients with First-Episode Schizophrenia
Shorter Duration of Psychosis Led to Improved Outcomes in Patients with First-Episode Schizophrenia

DUI=duration of untreated illness; DUP=duration of untreated psychosis.

References
  1. Owens DC et al. Br J Psychiatry. 2010;196(4):296-301.
  2. Primavera D et al. Ann Gen Psychiatry. 2012;11(1):21
file_download Download slide in HQ
The Value of a Support System
The Value of a Support System

CATIE=Clinical Antipsychotic Trials of Intervention Effectiveness.

References
  1. Glick ID et al. J Clin Psychopharmacol. 2011;31(1):82-85.
file_download Download slide in HQ
Family-Supervised Treatment Led to Significant Improvement in Symptoms and Functioning
Family-Supervised Treatment Led to Significant Improvement in Symptoms and Functioning

Intervention involved supervised treatment in outpatients for schizophrenia (STOPS). GAF=global assessment of functioning; PANSS™=Positive and Negative Syndrome Scale, a trademark of Multi-Health Systems, Inc.

References
  1. Farooq S et al. Br J Psychiatry. 2011;199(6):467-472.
file_download Download slide in HQ
Involving Patients in Their Own Care Increases Knowledge About Their Disease
Involving Patients in Their Own Care Increases Knowledge About Their Disease

*  Knowledge was assessed with a 7-item questionnaire about the patient’s disease and its treatment.

COMRADE=Combined Outcome Measure for Risk Communication and Treatment Decision Making Effectiveness.

References
  1. Hamann J et al. Acta Psychiatr Scand. 2006;114(4):265-273.
file_download Download slide in HQ

Related content

grid_view Slide Deck
Major depressive disorder (MDD) – Definitions and Diagnosis

This slide deck offers a comprehensive overview of Major Depressive Disorder (MDD), including its definitions, diagnostic criteria, symptom profiles, clinical course, differential diagnoses, and validated rating tools based on DSM-5-TR and ICD-11 guidelines.

02.07.2025 Depression
image Image Graphic showing extracellular, multimerization, and intracellular targets of alpha-synuclein for therapeutic intervention in Parkinson’s disease
Possible α-synuclein targets for development of therapies for Parkinson’s disease

Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease

26.06.2025 Parkinson’s Disease
image Image Chart showing progression of functional decline in Parkinson’s disease with different treatment approaches, from symptomatic benefit to disease modification.
Disease modification in Parkinson’s disease

Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure

26.06.2025 Parkinson’s Disease